



The subscription price for exercise of warrants of series TO3 in Alzinova has been set at SEK 2.17 per share

Alzinova AB ("Alzinova" or the "Company") completed a rights issue of units on Nasdaq First North Growth Market in June 2022. One (1) unit consisted of five (5) shares and four (4) warrants of series TO3 (the "Warrants"). Each Warrant gives the right to subscribe for one (1) new share in the Company. The subscription price for the Warrants has been set to 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the measurement period, which runs from and including March 23, 2023 to and including April 5, 2023, however not more than SEK 3.15 and not less than the quota value for the Company's shares. The volume-weighted average price of the Company's share during the measurement period amounted to approximately SEK 3.10 and thus the subscription price has been set at SEK 2.17. The subscription period for the Warrants runs during the period from and including April 11, 2023 to and including April 25, 2023.

If all Warrants are exercised, the Company will receive approximately SEK 28.1 million, before issuing costs. In order for the Warrants not to expire without value, it is required that the holder actively subscribes for shares no later than April 25, 2023, or alternatively sells the Warrants no later than April 21, 2023. Please note that some trustees may close their registration earlier than April 25, 2023.

Summarized terms for the Warrants:

Exercise period: April 11, 2023 – April 25, 2023.

Subscription price: SEK 2.17 per share.

Issue volume: 12,967,612 Warrants. If all the Warrants are exercised, 12,967,612 shares are issued, and the Company will receive approximately SEK 28.1 million before issuing costs.

Last day for trading with Warrants: April 21, 2023.

Share capital and dilution: If all Warrants are exercised the share capital will increase with SEK 3,410,481.956, from SEK 8,526,205.942 to SEK 11,936,687.898. The number of shares will increase with 12,967,612 shares if all Warrants are exercised, from 32,416,034 shares to 45,386,646 shares. The dilution at full exercise of all Warrants amounts to approximately 28.6 percent of the number of shares and votes in the Company.



Note that the Warrants that are not exercised at the latest April 25, 2023, or sold at the latest April 21, 2023, will expire without value. For the Warrants not to lose their value, the holder must actively subscribe for new shares or sell the Warrants.

Advisers

Mangold Fondkommission AB is the financial adviser, Fredersen Advokatbyrå AB is the legal adviser and Shark Communication is the communication adviser to the Company in connection with the exercise of the warrants of series TO3.

For questions regarding the Warrants, please contact:

Mangold Fondkommission AB
E-mail: emissioner@mangold.se

For more information, please contact:

Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Attachments

The subscription price for exercise of warrants of series TO3 in Alzinova has been set at SEK 2.17 per share